Search clinical trials for: Atogepant

Total 23 results

AbbVie

Recruiting

Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity in Adult Participants With Migraine (ECLIPSE)

Migraine

United Kingdom
IRCCS San Raffaele Roma

Not yet recruiting

Atogepant in Real Life in Italy (GIANT) (GIANT)

Migraine, Prophylaxis
AbbVie

Recruiting

Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine (Release)

Migraine

Japan
AbbVie

Recruiting

An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants (COBRA)

Migraine

Israel
AbbVie

Recruiting

Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine (TEMPLE)

Migraine

Belgium, Canada, Germany, Poland, Portugal, France, Italy, Hungary, Czechia, Israel, Austria, United Kingdom
AbbVie

Recruiting

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine (Kaleidoscope)

Episodic Migraine

United States, Puerto Rico, Spain, Canada, Netherlands, Israel, Sweden, Poland, Hungary, France, Denmark, Japan, United Kingdom, Italy, Romania, Belgium
AbbVie

Recruiting

An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants (COURAGE II)

Migraine

United States
AbbVie

Recruiting

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Chronic Migraine

United States
AbbVie

Recruiting

Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy (P22-392)

Migraine

United States
AbbVie

Active, not recruiting

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

Chronic Migraine | Episodic Migraine

United States, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, United Kingdom
AbbVie

Active, not recruiting

A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine

Chronic Migraine | Episodic Migraine

Japan
The Cleveland Clinic

Enrolling by invitation

Migraine Medication Effects on Urinary Symptoms

Overactive Bladder | Migraine | Migraine Disorders | Overactive Detrusor | Interstitial Cystitis | Overactive Bladder Syndrome | Bladder Pain Syndrome

United States
AbbVie

Completed

Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers

Healthy Volunteers

United States
AbbVie

Enrolling by invitation

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine

Episodic Migraine

United States, Canada, Denmark, Hungary, Italy, Poland, Puerto Rico, Spain, United Kingdom, Israel, Japan, Sweden
Allergan

Completed

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. (ELEVATE)

Episodic Migraine

United States, Australia, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden, United Kingdom
Allergan

Completed

Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine

Chronic Migraine

China
AbbVie

Completed

Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine (TANDEM)

Episodic Migraine

United States
Allergan

Completed

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Chronic Migraine

United States, Australia, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Spain, Sweden, Taiwan, United Kingdom
AbbVie

Completed

Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine

Migraine

United States
Allergan

Completed

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Episodic Migraine

United States
Allergan

Completed

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

Episodic Migraine

United States
Allergan

Completed

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

Episodic Migraine

United States
Allergan

Completed

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

Migraine, With or Without Aura

United States

3

Subscribe